 ERYTECH Pharma Nasdaq Euronext: ERYP, a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today provided a business update and reported its financial results for the fourth quarter and year ended December 31, 2019. 2019 has been a year of tremendous execution towards realizing our vision of helping cancer patients to live longer and better, said Gil Beyen, CEO of ERYTECH. 